|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Acambis plc, of Cambridge, UK, initiated a Phase I trial of its universal influenza vaccine candidate, ACAM-FLU-A. The vaccine is designed to target all A strains of the influenza virus. The randomized, double-blind, placebo-controlled study in the U.S. is investigating safety, tolerability and its ability to generate an immune response. The trial in up to 80 healthy subjects ages 18 to 40 also will assess two adjuvants to determine whether they improve the effect of the vaccine on the immune system. The recombinant vaccine uses a hepatitis B core protein to present M2e, the extracellular domain of the influenza ion channel protein M2, to the immune system.
o ...